Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) decreased the incidence of interstitial pneumonia in B cell non-Hodgkin lymphoma patients receiving combined chemotherapy plus rituximab
Research Square (Research Square)